Literature DB >> 25414370

Improved outcome with combined US/CT guidance as compared to US guidance in percutaneous radiofrequency ablation of small renal masses.

Mats Andersson1, Farida Hashimi2, David Lyrdal3, Sven Lundstam3, Mikael Hellström2.   

Abstract

BACKGROUND: When performing percutaneous radiofrequency ablation (RFA) of small renal masses (SRM), use of optimized periprocedural image guidance is essential to secure curative outcome of the treatment.
PURPOSE: To retrospectively compare the short-term radiological and clinical outcomes of RFA under combined ultrasound (US) and computed tomography (CT) guidance with that of a previously performed US-guided series at the same institution.
MATERIAL AND METHODS: From November 2009 to November 2013, 60 patients (mean age, 70.1 years; range, 34-86 years) with renal masses measuring in the range of 13-50 mm in maximal diameter (mean diameter, 25.4 ± 6.8 mm) underwent percutaneous RFA with combined US/CT guidance. The technical success rate, recurrence-free survival, rate of complications, and the percentage change in the estimated glomerular filtration rate (eGFR) were compared with that of a previously published series of 41 patients with SRM treated with US-guided RFA between November 2002 and December 2008.
RESULTS: The tumor and patient characteristics were similar between the two treatment groups. The primary and secondary technical success rate was significantly higher in the group treated with combined US/CT guidance compared with the group treated with US guidance alone (100% and 100% vs. 82% and 91%, respectively). The local recurrence-free survival was significantly better in the combined US/CT-guided group than in the US-guided group (P = 0.016). There was no significant difference in the rate of overall complications (13% vs. 17%) or the mean percentage decrease in the eGFR after the respective treatment (1.1 ± 18.3% vs. 5.0 ± 11.7%).
CONCLUSION: The use of combined US/CT guidance when performing renal RFA resulted in superior primary and short-term outcome compared to the use of US guidance alone in patients treated at the same institution. © The Foundation Acta Radiologica 2014.

Entities:  

Keywords:  Abdomen/GI; ablation procedures; comparative studies; interventional; kidney; percutaneous

Mesh:

Year:  2014        PMID: 25414370     DOI: 10.1177/0284185114558974

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  5 in total

1.  Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study.

Authors:  Saeed Dabestani; Andreas Thorstenson; Per Lindblad; Ulrika Harmenberg; Börje Ljungberg; Sven Lundstam
Journal:  World J Urol       Date:  2016-02-05       Impact factor: 4.226

Review 2.  Tips and tricks for a safe and effective image-guided percutaneous renal tumour ablation.

Authors:  Giovanni Mauri; L Nicosia; G M Varano; G Bonomo; P Della Vigna; L Monfardini; F Orsi
Journal:  Insights Imaging       Date:  2017-05-12

3.  Local recurrence of renal cell carcinoma successfully treated with fusion imaging-guided percutaneous thermal ablation.

Authors:  Nicola Camisassi; Giovanni Mauri; Paolo Della Vigna; Guido Bonomo; Gianluca Maria Varano; Daniele Maiettini; Franco Orsi
Journal:  Ecancermedicalscience       Date:  2020-07-13

4.  Radiofrequency ablation using real-time ultrasonography-computed tomography fusion imaging improves treatment outcomes for T1a renal cell carcinoma: Comparison with laparoscopic partial nephrectomy.

Authors:  Dong Jin Chung; Hyun Hwang; Dong Wan Sohn
Journal:  Investig Clin Urol       Date:  2022-03

5.  Long-Term Follow-Up Outcomes after Percutaneous US/CT-Guided Radiofrequency Ablation for cT1a-b Renal Masses: Experience from Single High-Volume Referral Center.

Authors:  Giovanni Mauri; Francesco Alessandro Mistretta; Guido Bonomo; Nicola Camisassi; Andrea Conti; Paolo Della Vigna; Matteo Ferro; Stefano Luzzago; Daniele Maiettini; Gennaro Musi; Nicolò Piacentini; Gianluca Maria Varano; Ottavio de Cobelli And Franco Orsi
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.